Certezas e incertidumbres | 03 ENE 22

COVID prolongado en niños y adolescentes

Revisión de estudios sobre síntomas persistentes luego de una infección por Covid en niños y adolescentes.
Autor/a: Petra Zimmermann, Laure F. Pittet, and Nigel Curtis. Pediatr Infect Dis J 2021 Dec 1;40(12)
INDICE:  1. Texto principal | 2. Referencia bibliográfica
Referencia bibliográfica

1. Götzinger F, Santiago-García B, Noguera-Julián A, et al; ptbnet COVID19 Study Group. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4:653–661.

2. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020;39:355–368.

3. Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020;174:882–889.

4. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109:1088– 1095.

5. Zimmermann P, Curtis N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age related difference in severity of SARS-CoV-2 infections [published online ahead of print December 1, 2020]. Arch Dis Child. doi: 10.1136/archdischild-2020-320338.

6. Zimmermann P, Curtis N. COVID-19 in children, pregnancy and neonates: a review of epidemiologic and clinical features. Pediatr Infect Dis J. 2020;39:469–477.

7. Uka A, Buettcher M, Bernhard-Stirnemann S, et al. Factors associated with hospital and intensive care admission in paediatric SARS-CoV-2 infection: a prospective nationwide observational cohort study. Eur J Pediatr. In review.

8. Ward JL, Harwood R, Smith C, et al. Risk factors for intensive care admission and death amongst children and young people admitted to hospital with COVID-19 and PIMS-TS in England during the first pandemic year. medRxiv. 2021. doi:10.1101/2021.07.01.21259785

9. WHO. COVID-19 detailed surveillance data dashboard. Available at: https:// covid19.who.int. Accessed July 27, 2021.

10. Beck A, Gandhi M. Adjudicating reasons for hospitalization reveals that severe illness from COVID-19 in children is rare. Hosp Pediatr. 2021;11:e159–e160.

11. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasakilike disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395:1771–1778.

12. Viner RM, Whittaker E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. Lancet. 2020;395:1741–1743.

13. Moreira A. Kawasaki disease linked to COVID-19 in children. Nat Rev Immunol. 2020;20:407.

14. Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 2020;369:m2094.

15. Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395:1607–1608.

16. Levin M. Childhood multisystem inflammatory syndrome—a new challenge in the pandemic. N Engl J Med. 2020;383:393–395.

17. Moraleda C, Serna-Pascual M, Soriano-Arandes A, et al; EPICO-AEP Working Group. Multi-inflammatory syndrome in children related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Spain. Clin Infect Dis. 2021;72:e397–e401.

18. Cheung EW, Zachariah P, Gorelik M, et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA. 2020;324:294–296.

19. Whittaker E, Bamford A, Kenny J, et al; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020;324:259–269.

20. Payne AB, Gilani Z, Godfred-Cato S, et al. Incidence of multisystem inflammatory syndrome in children among US persons infected with SARSCoV-2. JAMA Network Open. 2021;4:e2116420.

21. Bliddal S, Banasik K, Pedersen OB, et al. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Sci Rep. 2021;11:13153.

22. Mandal S, Barnett J, Brill SE, et al; ARC Study Group. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76:396–398.

23. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601–615.

24. Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. The Lancet. 2021;398:747–758.

25. Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. Available at https://www. ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1july2021. Accessed July 1, 2021.

26. Buonsenso D, Munblit D, De Rose C, et al. Preliminary evidence on long COVID in children. Acta Paediatr. 2021;110:2208–2211.

27. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 Longterm effects of COVID-19: a systematic review and meta-analysis. medRxiv. 2021. doi:10.1038/s41598-021-95565-8

28. Sigfrid L, Drake TM, Pauley E, et al. Long Covid in adults discharged from UK hospitals after Covid-19: a prospective, multicentre cohort study using the ISARIC WHO clinical characterisation protocol. medRxiv. 2021. doi: 10.1016/j.lanepe.2021.100186.

29. Munblit D, Bobkova P, Spiridonova E, et al. Risk factors for long-term consequences of COVID-19 in hospitalised adults in Moscow using the ISARIC global follow-up protocol: StopCOVID cohort study. medRxiv. 2021. doi:10.1101/2021.02.17.21251895

30. Blankenburg J, Wekenborg MK, Reichert J, et al. Mental health of Adolescents in the pandemic: long-COVID19 or long-pandemic syndrome? medRxiv. 2021. doi:10.1101/2021.05.11.21257037.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023